Cancer Research Meeting Calendar Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lal, A.
Right arrow Articles by Riggins, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lal, A.
Right arrow Articles by Riggins, G. J.
[Cancer Research 62, 3335-3339, June 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Mutant Epidermal Growth Factor Receptor Up-Regulates Molecular Effectors of Tumor Invasion1

Anita Lal, Chad A. Glazer, Holly M. Martinson, Henry S. Friedman, Gary E. Archer, John H. Sampson and Gregory J. Riggins2

Departments of Pathology [A. L., C. A. G., H. M. M., J. H. S, G. J. R.] and Surgery [H. S. F., G. E. A., J. H. S.], Duke University Medical Center, Durham, North Carolina 27710

The gene most commonly altered in human glioblastomas is the epidermalgrowth factor receptor (EGFR). We profiled transcripts induced by mutantEGFR to better understand its role in tumor progression. The pattern found suggested enhanced tumor invasion. The highly induced genes included extracellular matrix components, metalloproteases, and a serine protease. We confirmed that mutant EGFR did make glioblastoma cells both more motile and invasive using in vitro assays. Furthermore, inhibitors of EGFR (OSI-774 and Tyrphostin AG1478) selectively down-regulated these molecular effectors in glioblastoma cells, eliminating enhanced invasion.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. A. Bax, N. Gaspar, S. E. Little, L. Marshall, L. Perryman, M. Regairaz, M. Viana-Pereira, R. Vuononvirta, S. Y. Sharp, J. S. Reis-Filho, et al.
EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines
Clin. Cancer Res., September 15, 2009; 15(18): 5753 - 5761.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. V. Lu, S. Zhu, A. Cvrljevic, T. T. Huang, S. Sarkaria, D. Ahkavan, J. Dang, E. B. Dinca, S. B. Plaisier, I. Oderberg, et al.
Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients
Cancer Res., September 1, 2009; 69(17): 6889 - 6898.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
G. Karpel-Massler, U. Schmidt, A. Unterberg, and M.-E. Halatsch
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Mol. Cancer Res., July 1, 2009; 7(7): 1000 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Lal, C. R. Goodwin, Y. Sang, C. A. Foss, K. Cornet, S. Muzamil, M. G. Pomper, J. Kim, and J. Laterra
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts
Mol. Cancer Ther., July 1, 2009; 8(7): 1751 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-S. Guillamo, S. de Bouard, S. Valable, L. Marteau, P. Leuraud, Y. Marie, M.-F. Poupon, J.-J. Parienti, E. Raymond, and M. Peschanski
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Clin. Cancer Res., June 1, 2009; 15(11): 3697 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. L. Bearer, J. S. Lowengrub, H. B. Frieboes, Y.-L. Chuang, F. Jin, S. M. Wise, M. Ferrari, D. B. Agus, and V. Cristini
Multiparameter Computational Modeling of Tumor Invasion
Cancer Res., May 15, 2009; 69(10): 4493 - 4501.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
L. Li, A. Dutra, E. Pak, J. E. Labrie III, R. M. Gerstein, P. P. Pandolfi, L. D. Recht, and A. H. Ross
EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors
Neuro-oncol, January 1, 2009; 11(1): 9 - 21.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. A. Fromm, S. A. S. Johnson, and D. L. Johnson
Epidermal Growth Factor Receptor 1 (EGFR1) and Its Variant EGFRvIII Regulate TATA-Binding Protein Expression through Distinct Pathways
Mol. Cell. Biol., October 15, 2008; 28(20): 6483 - 6495.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
H.-D. Kim, T. W. Guo, A. P. Wu, A. Wells, F. B. Gertler, and D. A. Lauffenburger
Epidermal Growth Factor-induced Enhancement of Glioblastoma Cell Migration in 3D Arises from an Intrinsic Increase in Speed But an Extrinsic Matrix- and Proteolysis-dependent Increase in Persistence
Mol. Biol. Cell, October 1, 2008; 19(10): 4249 - 4259.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Martens, Y. Laabs, H. S. Gunther, D. Kemming, Z. Zhu, L. Witte, C. Hagel, M. Westphal, and K. Lamszus
Inhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2
Clin. Cancer Res., September 1, 2008; 14(17): 5447 - 5458.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. P. Mason and J. G. Cairncross
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas
Neurology, July 29, 2008; 71(5): 365 - 373.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. C. Brantley and E. N. Benveniste
Signal Transducer and Activator of Transcription-3: A Molecular Hub for Signaling Pathways in Gliomas
Mol. Cancer Res., May 1, 2008; 6(5): 675 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. Kim, J. M. Brush, P. A. Watson, N. A. Cacalano, K. S. Iwamoto, and W. H. McBride
Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation
Mol. Cancer Res., March 1, 2008; 6(3): 426 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. K. Nicholas, R. V. Lukas, N. F. Jafri, L. Faoro, and R. Salgia
Epidermal Growth Factor Receptor-Mediated Signal Transduction in the Development and Therapy of Gliomas
Clin. Cancer Res., December 15, 2006; 12(24): 7261 - 7270.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Sok, F. M. Coppelli, S. M. Thomas, M. N. Lango, S. Xi, J. L. Hunt, M. L. Freilino, M. W. Graner, C. J. Wikstrand, D. D. Bigner, et al.
Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
Clin. Cancer Res., September 1, 2006; 12(17): 5064 - 5073.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. B. Ramnarain, S. Park, D. Y. Lee, K. J. Hatanpaa, S. O. Scoggin, H. Otu, T. A. Libermann, J. M. Raisanen, R. Ashfaq, E. T. Wong, et al.
Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Cancer Res., January 15, 2006; 66(2): 867 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Aghi, P. Gaviani, J. W. Henson, T. T. Batchelor, D. N. Louis, and F. G. Barker II
Magnetic Resonance Imaging Characteristics Predict Epidermal Growth Factor Receptor Amplification Status in Glioblastoma
Clin. Cancer Res., December 15, 2005; 11(24): 8600 - 8605.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. C. Cuevas, A. L. Slocum, P. Jun, J. F. Costello, A. W. Bollen, G. J. Riggins, M. W. McDermott, and A. Lal
Meningioma Transcript Profiles Reveal Deregulated Notch Signaling Pathway
Cancer Res., June 15, 2005; 65(12): 5070 - 5075.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Zhang, Y.-f. Zhang, J. Bryant, A. Charles, R. J. Boado, and W. M. Pardridge
Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3667 - 3677.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Learn, T. L. Hartzell, C. J. Wikstrand, G. E. Archer, J. N. Rich, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson
Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme
Clin. Cancer Res., May 1, 2004; 10(9): 3216 - 3224.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Perez-Soler
HER1/EGFR Targeting: Refining the Strategy
Oncologist, February 1, 2004; 9(1): 58 - 67.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. L. Janmaat and G. Giaccone
Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, December 1, 2003; 8(6): 576 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Gilbertson, D. A. Hill, R. Hernan, M. Kocak, R. Geyer, J. Olson, A. Gajjar, L. Rush, R. L. Hamilton, S. D. Finkelstein, et al.
ERBB1 Is Amplified and Overexpressed in High-grade Diffusely Infiltrative Pediatric Brain Stem Glioma
Clin. Cancer Res., September 1, 2003; 9(10): 3620 - 3624.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. Hu, P. Guo, Q. Fang, H.-Q. Tao, D. Wang, M. Nagane, H.-J. Su Huang, Y. Gunji, R. Nishikawa, K. Alitalo, et al.
Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2
PNAS, July 22, 2003; 100(15): 8904 - 8909.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Mendelsohn and J. Baselga
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Matsuo, H. Sakurai, and I. Saiki
ZD1839, a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Shows Antimetastatic Activity Using a Hepatocellular Carcinoma Model
Mol. Cancer Ther., June 1, 2003; 2(6): 557 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. H. H. Schmidt, F. B. Furnari, W. K. Cavenee, and O. Bogler
Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization
PNAS, May 27, 2003; 100(11): 6505 - 6510.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Okada, E. E. Hurwitz, J. M. Esposito, M. A. Brower, C. L. Nutt, and D. N. Louis
Selection Pressures of TP53 Mutation and Microenvironmental Location Influence Epidermal Growth Factor Receptor Gene Amplification in Human Glioblastomas
Cancer Res., January 15, 2003; 63(2): 413 - 416.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.